Luminary Learning Gastrointestinal Disorder- Issue 1

12  • LUMINARY LEARNING: GASTROINTESTINAL DISORDERS 45. Abid S, Jafri W, Mumtaz K, et al. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Physicians Surg Pak. 2011;21(11):666–71. 46. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011;54(3):1063–70. 47. Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementationwith branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124(7):1792–801. 48. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3(7):705–13. 49. Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;5:Cd001939. 50. PlauthM, Cabre E, Riggio O, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25(2):285–94. 51. PlauthM,CabreE,CampilloB,etal.ESPENguidelinesonparenteral nutrition:hepatology.ClinNutr. 2009;28(4):436– 44. 52. Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57(6):2448–57. 53. Singh S, Kamath PS, Andrews JC, Leise MD. Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy. Hepatology. 2014;59(2):735–6. 54. An J, Kim KW, Han S, Lee J, Lim YS. Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy. Aliment Pharmacol Ther. 2014;39(12):1418–26. 55. Lynn AM, Singh S, Congly SE, et al. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transplant. 2016;22(6):723–31. 56. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836–46. 57. Leise MD, Poterucha JJ, Kamath PS, KimWR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc. 2014;89(2):241–53. 58. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46(6):1853–62. 59. Banares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57(3):1153–62. 60. Pares A, Deulofeu R, Cisneros L, et al. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care. 2009;13(1):R8. 61. Garcia-Martinez R, Rovira A, Alonso J, et al. Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transplant. 2011;17(1):38–46. 62. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–47. Source: Peeraphatdit T (Bee), Kamath PS, Leise MD. Latest concepts in inpatient hepatic encephalopathy management. In: Bajaj JS. (ed). Diagnosis and Management of Hepatic Encephalopathy: A Case-Based Guide. 1st ed. Switzerland: Springer International Publishing; 2018, pp. 77-97. DOI 10.1007/978-3-319-76798-7_6. © Springer International Publishing AG, part of Springer Nature 2018.